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During the 2003 severe acute respiratory syndrome
(SARS) outbreak, a real-time quantitative polymerase
chain reaction, which targets the nucleocapsid gene at the
3' end of the viral genome, was established to detect and
identify the SARS-associated coronavirus. We describe the
use of this assay to screen >700 clinical samples. 
S
evere acute respiratory syndrome (SARS) is a new
infectious disease of humans, first recognized in late
February 2003 in Hanoi, Vietnam. The disease spread rap-
idly, with cases reported from 29 countries on five conti-
nents over 4 months (1–7). By July 3, 2003, this epidemic
resulted in 8,439 reported cases globally, of which 812
were fatal (8). Rapid identification of the causal agent as a
novel coronavirus (SARS-CoV) represents an extraordi-
nary achievement in the history of global health and helped
to contain the epidemic (7). Nonetheless, the epidemiolo-
gy and pathogenesis of SARS remain poorly understood,
and definitive diagnostic tests or specific treatments are
not established. Since the origin of the virus and its animal
reservoirs remain to be defined, the potential for recur-
rence is unknown. This fact underscores the importance of
establishing sensitive and efficient methods for diagnosis
and surveillance. 
Immunofluorescence and enzyme-linked immunosor-
bent assays (ELISA) are reported to inconsistently detect
antibodies to SARS-CoV before day 10 or 20 after the
onset of symptoms, respectively (7,9). Thus, although
helpful in tracking the course of infection at the population
level, these serologic tools have less usefulness in detect-
ing infection at early stages, when there may be potential
to implement therapeutic interventions or measures, such
as quarantine that may reduce the risk for transmission to
naïve persons. In contrast, polymerase chain reaction
(PCR)–based assays have the potential to detect infection
at earlier time points. We describe a sensitive real-time
PCR assay that can be readily standardized across labora-
tories and report its use in a survey of more than 700 sam-
ples from persons diagnosed with probable SARS during
the 2003 epidemic in Beijing.
The Study
Primers and probe were selected in the N (nucleocapsid
protein) gene region at the 3′ end of the SARS-CoV
genome by using Primer Express Software (PE Applied
Biosystems, Foster City, CA). The primer set used was:
Taq-772F 5′-AAGCCTCGCCAAAAACGTAC (forward)
and Taq-1000R 5′-AAGTCAGCCATGTTCCCGAA
(reverse), Taq-955T 5′-FAM-TCACGCATTGGCATG-
GAAGTCACAC-T-TAMRA (probe), labeled with the
reporter FAM (6-carboxyfluorescein) and the quencher
TAMRA (6-carboxytetramethylrhodamine) (TIB Molbiol,
Berlin, Germany). 
A calibration standard was generated by PCR amplifi-
cation of a 1,277-bp fragment comprising part of the N
open reading frame (ORF) and the 3′ noncoding region
(Co-STND-U275, 5′-CCCGACGAGTTCGTGGTGGTG;
Co-STND-L1529, 5′-GCGTTACACATTAGGGCTCTTC
CATA). The product was cloned into vector pGEM-Teasy
(Invitrogen, Carlsbad, CA), and serial dilutions of lin-
earized plasmid were used to optimize the assay. RNA
standards were generated by in vitro transcription of lin-
earized plasmid DNA using a mMESSAGE mMACHINE
T7 kit as recommended by the manufacturer (Ambion,
Austin, TX). A portion of the construct (nucleotides
682–1105 of the N ORF) was modified through site-
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script.directed mutagenesis, to distinguish plasmid-derived prod-
ucts from authentic products in diagnostic applications.
Mutations introduced were an A to G change at position
845 of the N ORF, and an A to C change at position 866,
creating a unique ApaI restriction site. 
Detection of live virus was assessed by using super-
natant from virus-infected Vero E6 cells (isolate BJ01; 4th
passage; 108 TCID50/mL) tenfold diluted to 10–12 in tissue
culture media. RNAfrom 140-µL aliquots of each dilution
was extracted and resuspended in 60 µL of DEPC-treated
water for reverse transcription (9 µL RNA/20-µL reaction)
and PCR (5 µL/assay). 20 µL of each virus dilution were
spiked into 180 µL of clarified supernatant of a fecal
preparation to simulate clinical specimens, and RNA from
140-µL aliquots was extracted and processed as above.
Clinical materials, including 326 fecal and 426 whole
blood samples, were collected from Chaoyang Hospital,
301 Hospital, You’an Hospital, and Xuanwu Hospital,
Beijing. All persons had a diagnosis of probable SARS
according to World Health Organization (WHO) criteria.
For analysis of fecal samples, 1 g of stool was suspended
in 1 mL of phosphate-buffered saline, mixed vigorously,
and centrifuged for 10 min at 3,000 g, 4°C. Supernatant
was collected for RNA extraction and PCR analysis. For
analysis of blood samples, whole blood was fractionated
using Ficoll Paque (Amersham Pharmacia, England).
Plasma was collected and immunoglobulin (Ig) G and IgM
levels were determined with an ELISAkit from the Beijing
Genomics Institute (Beijing, China). Peripheral blood
mononuclear cells were collected and RNA extracted by
using the QiaAmp Viral RNA Mini Kit (Qiagen,
Germany). Nine microliters total RNA was reverse tran-
scribed (SuperScript II Transcriptase, Invitrogen), and
2  µL of cDNA subjected to PCR by using a TaqMan
Universal Master Mix kit (PE Applied Biosystems) on an
ABI Prism 7900 HT sequence detector (PE Applied
Biosystems). Thermocycling conditions were: 2 min 50°C
(AmpErase UNG), 10 min 95°C (polymerase activation);
45 cycles of 15s 95°C denaturation, and 1 min 60°C
annealing/extension.
Conclusions
A standard curve of plasmid concentration versus
threshold cycle was generated with a cloned version of the
3′ terminal portion of the viral genome. A correlation
coefficient (r2) of 0.9913 showed a linear relationship
between threshold cycle (Ct) and plasmid concentration
(0–105 copies) (Figure 1A). The detection limit for plas-
mid DNA was <5 copies per assay (Ct = 42.66). A linear
relationship was consistently obtained for input loads of
101–105 copies per assay. 
Standards for RT-PCR were generated by in vitro tran-
scription of RNA from linearized plasmid template with
T7 polymerase. Logarithmic dilutions of the synthesized
RNA yielded results comparable to the DNA standards
(r2 = 0.9950; Figure 1B). 
Supernatant from infected Vero E6 cells was serially
diluted to determine the detection limit for live virus.
Analysis of RNA extracted from logarithmic dilutions
indicated a detection threshold of 0.0005 TCID50 (10–9
dilution; 0.1 TCID50/mL; 0.0005 TCID50 per assay well).
The threshold for detection of SARS-CoV in spiked fecal
samples was 0.005 TCID50 (10–7 dilution; 1 TCID50/mL;
0.005 TCID50 per assay well) (data not shown).
Materials from persons who had probable SARS
included 326 fecal samples and 426 blood samples.
Control specimens collected during the outbreak from
healthy persons included 16 fecal samples and 82 blood
samples. The detection rate in fecal samples was 27% dur-
ing the first 20 days after onset of symptoms (Table, Figure
2A). In the 20 days that followed, the detection rate
declined to 16% to 18%, but even after >40 days, 9% of
samples gave a positive reading. Asimilar time course was
observed in the analysis of blood samples; however, a
higher detection rate of 45% to 49% was obtained (note
that only 11 of the samples were matched for blood and
feces). During the first 20 days after onset of symptoms,
the detection rate of RT-PCR in blood was significantly
higher than that for IgM (10%–24%) or IgG antibodies
(13%–15%) (Table, Figure 2B). Twenty-one to 40 days
after onset of symptoms, serologic findings were more fre-
quently positive than RT-PCR. 
Of the 16 fecal and 82 blood samples obtained from
healthy persons, one blood sample yielded a positive result
in RT-PCR (confirmed by repeated assays). Because the
sample was collected during the outbreak, it may represent
a true infection in a person who was not yet symptomatic
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Figure 1. Standard curve and amplification plot using serial dilu-
tions of plasmid DNA (A) or of cRNA (B).or who did not have classical symptoms (no clinical infor-
mation for the period after sampling was available).
We also analyzed 180 sputum and 76 throat-washing
samples from an unrelated cohort of persons with a diag-
nosis of probable SARS, for which the time after onset of
symptoms had not been reported. The RT-PCR detection
rate obtained in these samples was 63% for sputum sam-
ples, and 15% for throat washing samples (data not shown).
It was not possible during the Beijing outbreak to
obtain clinical materials in a prospective serial fashion
from a defined SARS-CoV–infected patient cohort. Thus,
some samples represent persons with respiratory symp-
toms caused by pathogens other than SARS-CoV (10).
However, confidence in the clinical criteria is enhanced by
an 87% seropositivity in samples taken 31–40 days after
onset of symptoms. 
Current real-time RT-PCR assays allow sensitive detec-
tion of SARS-CoV nucleic acid in clinical specimens by
targeting N gene sequence, as shown here, or pol gene
sequence (11–15). A major advantage to real-time PCR
platforms is that amplification and analysis are completed
in a closed system. Thus, the risk of contamination, which
can confound conventional (frequently nested) RT-PCR
protocols (5,11,16), is markedly reduced. Whether differ-
ent positivity rates reported for various SARS-CoV assays
(12–14,17) reflect true differences in assay performance,
or merely differences in specimen type or differences in
sample preparation (13), will only become apparent after
comparative quality control tests using identical samples
in the various assays and laboratories. Using calibrated
DNA and RNA standards, we achieved comparable results
with the assay reported here in the New York and Beijing
laboratories.
RNA integrity is a critical determinant of sensitivity in
RT-PCR SARS-CoV assays. Samples were not collected at
clinical sites with the objective of nucleic acid analysis.
Additionally, protocols adopted by the various hospitals
for sample collection, handling, and storage were not uni-
form. Nonetheless, RT-PCR analysis resulted in consistent
results for all 11 cases of matching feces and blood sam-
ples. Furthermore, all blood samples seropositive during
the first 20 days after onset of symptoms were also posi-
tive in RT-PCR. Of the 48 RT-PCR positive samples col-
lected 21–40 days after onset of symptoms, 45 were also
seropositive.
RT-PCR analysis of blood was a less sensitive index of
infection than immunologic assays at later time points
(21–40 days after onset of symptoms). However, 16% of
blood samples and 18% of fecal samples contained
SARS-CoV RNA>31–40 days after onset of symptoms. A
similar duration of persistence of SARS sequences in
stool has been observed by Ren et al. (17). Whether infec-
tious virus is present at these later time points remains to
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Table. Summary of clinical samples  
1–10 d  11–20 d  21–30 d  31–40 d  >40 d 
Specimens  Total patients  pos  neg  pos  neg  pos  neg  pos  neg  pos  neg 
Feces PCR  326  10  27  19  52  12  65  12  55  7  67 
Blood PCR  426  28  34  20  21  22  143  26  132  NA  NA 
Blood IgG  426  6  56  10  31  82  83  138  20  NA  NA 
Blood IgM  426  8  54  6  35  63  102  82  76  NA  NA 
apos, positive; neg, negative; PCR, polymerase chain reaction; Ig, immunoglobulin; NA, not available. 
Figure 2. (A) real-time polymerase chain reaction (PCR) analysis
of fecal samples; (B) real-time PCR, immunoglobulin (Ig) M and
IgG analysis of blood samples.
A
Bbe determined; nonetheless, our findings indicate that
long-term monitoring may be required to control dissem-
ination of disease. 
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